Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $9.23, down 9.06% from the previous trading session, underperforming the S&P 500's daily loss of 0.33% [1] - Over the past month, the company's shares gained 6.17%, outperforming the Medical sector's loss of 1.02% and the S&P 500's unchanged performance [1] Earnings Projections - The upcoming earnings release is projected to show an earnings per share (EPS) of -$1.8, reflecting a 1.1% increase from the same quarter last year [2] - Revenue is anticipated to be $37 million, indicating a 15.62% decrease from the same quarter last year [2] Annual Estimates - For the annual period, the Zacks Consensus Estimates predict an EPS of -$5.94 and revenue of $173 million, representing changes of +42.66% and -23.8% from the previous year, respectively [3] - Recent changes to analyst estimates suggest a shifting landscape in near-term business trends, with positive alterations indicating analyst optimism [3] Zacks Rank and Industry Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record, with stocks rated 1 producing an average annual return of +25% since 1988 [5] - Ginkgo Bioworks currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate remaining unchanged over the last 30 days [5] - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 86, placing it in the top 36% of over 250 industries [6]